Thursday, January 20, 2022, San Francisco, California, 6:15 PM – 7:45 PM Pacific Time (9:15 PM – 10:45 PM Eastern Time)

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Gastroesophageal Cancers

Part 2 of a 3-Part CME Symposium Series Held in Conjunction with the 2022 Gastrointestinal Cancers Symposium

Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Program Schedule — Pacific Time
6:00 PM – 6:15 PM — Registration
6:15 PM – 7:45 PM — Educational Dinner Meeting

Meeting Room
Golden Gate Ballroom - Salon A (B2 Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Francisco, CA, preregistration is required as seating is limited.  
 
Faculty
Daniel Catenacci, MD
Associate Professor, Department of Medicine
Section of Hematology and Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research
Comprehensive Cancer Center
The University of Chicago Medical Center
and Biological Sciences
Chicago, Illinois

Yelena Y Janjigian, MD
Associate Attending Physician
Associate Professor, WCMC
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York


Eric Van Cutsem, MD, PhD
Professor of Medicine
Digestive Oncology
University Hospitals Leuven
Leuven, Belgium

Moderator
Samuel J Klempner, MD
Associate Professor
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts


This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Coherus BioSciences, Daiichi Sankyo Inc and Lilly.
Program Schedule — Pacific Time
6:00 PM – 6:15 PM — Registration
6:15 PM – 7:45 PM — Educational Dinner Meeting

MODULE 1: Current and Future Front-Line Management of Advanced Gastric and Gastroesophageal Junction (GEJ) Cancer

MODULE 2: Contemporary Management of HER2-Positive Advanced Gastric and GEJ Cancer

MODULE 3: Selection and Sequencing of Therapy for Relapsed Gastric and GEJ Cancer

MODULE 4: Key Research Informing the Treatment of Localized and Advanced Esophageal Cancer

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to personalize the selection of first-line therapy for locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
  • Describe the published research data with immune checkpoint inhibitors alone or in combination with chemotherapy in the management of gastric, GEJ and esophageal cancer, and optimally integrate these strategies into nonresearch treatment algorithms.
  • Optimally incorporate available therapeutic agents and regimens into the management of HER2-negative metastatic gastric, GEJ and esophageal cancer in patients who have experienced disease progression on front-line chemotherapy or chemoimmunotherapy.
  • Appraise clinical trial findings with and the clinical applicability of the use of adjuvant anti-PD-1 antibody therapy for patients with resected esophageal/GEJ cancer who have received neoadjuvant chemoradiation therapy and have residual pathologic disease.
  • Recall available data with novel HER2-targeted agents and strategies for patients with newly diagnosed or previously treated HER2-overexpressing gastric or GEJ cancer, and identify candidates who may be appropriate for these approaches.
  • Recognize common and rare side effects associated with approved and investigational agents used in the care of patients with gastroesophageal cancers, and apply this information to develop appropriate and effective supportive management plans.
  • Review the rationale for, available data with and ongoing research evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Coherus BioSciences, Daiichi Sankyo Inc and Lilly.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room
Golden Gate Ballroom - Salon A (B2 Level)

Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Convention Center where the 2022 Gastrointestinal Cancers Symposium is taking place.

 
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

There is no fee to participate in this program or live webcast of this event.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live broadcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not official events of the 2022 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.